Hemophilia B
Conditions
Keywords
prophylaxis treatment, episodic treatment
Brief summary
The primary objective of the study was to evaluate the safety of recombinant coagulation factor IX Fc fusion protein (rFIXFc, BIIB029) in previously untreated patients (PUPs) with severe hemophilia B. Secondary objectives were to evaluate the efficacy of rFIXFc in the prevention and treatment of bleeding episodes in PUPs, and to evaluate rFIXFc consumption for prevention and treatment of bleeding episodes in PUPs.
Interventions
BIOLOGICALrFIXFc
Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
Sponsors
Swedish Orphan Biovitrum
Bioverativ, a Sanofi company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Weight \>=3.5 kilogram at the time of informed consent. * Severe hemophilia B was defined as less than or equal to (\<=)2 International Units per deciliter (IU/dL) (\<=2 percent \[%\]) endogenous FIX documented in the medical record or as tested during the Screening Period. Key
Exclusion criteria
* History of positive inhibitor testing. A prior history of inhibitors was defined based on a participant's historical positive inhibitor test using the local laboratory Bethesda value for a positive inhibitor test (that is equal to or above lower limit of detection). * History of hypersensitivity reactions associated with any rFIXFc administration. * Exposure to blood components or injection with a coagulation factor IX (FIX) concentrate (including plasma derived) other than rFIXFc. * Injection with commercially available rFIXFc more than 28 days prior to Screening. * More than 3 injections of commercially available rFIXFc prior to confirmation of eligibility. * Other coagulation disorders in addition to hemophilia B. * Any concurrent clinically significant major disease that, in the opinion of the Investigator, would have made the participant unsuitable for enrollment (example HIV infection with cluster of differentiation 4 (CD4) lymphocyte count less than (\<)200 cells/microliter (mcL) or a viral load greater than (\>)200 particles/mcL, or any other known congenital or acquired immunodeficiency). * Current systemic treatment with chemotherapy and/or other immunosuppressant drugs. Use of steroids for treatment of asthma or management of acute allergic episodes or otherwise life-threatening episodes was allowed. Treatment in these circumstances should not have exceeded a 14-day duration. * Participation within the past 30 days in any other clinical study involving investigational treatment. * Current enrollment in any other clinical study involving investigational treatment. * Inability to comply with study requirements. * Other unspecified reasons that, in the opinion of the Investigator or Bioverativ, would have made the participant unsuitable for enrollment. NOTE: Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay | Up to 3 years | Development of an inhibitor was defined as an inhibitor test result of \>= 0.60 Bethesda units per milliliter (BU/mL) that was confirmed by a second test result of \>=0.60 BU/mL from a separate sample, drawn 2 to 4 weeks after the date when the original sample was drawn, with both tests performed by the central laboratory using Nijmegen-modified Bethesda assay. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Annualized Number of Spontaneous Joint Bleeding Episodes | Up to 3 years | Bleeding episodes were classified as spontaneous if parent/caregiver/participant records a bleeding event when there is no known contributing factor such as a definite trauma or antecedent strenuous activity. Annualized spontaneous joint bleeding episodes=(Total number of spontaneous joint bleeding episodes during efficacy period (EP) divided by total number of days during EP)\*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc per treatment regimen excluding major and minor surgical/rehabilitation periods and large injection intervals (\>28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study. |
| Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Up to 3 years | Using e-diary, each participant's parent/caregiver rated treatment response to any bleeding episode (BE) at approximately 8 to 12 hours from time of injection and prior to additional doses of rFIXFc given for same BE using 4-point scale:- 1=Excellent: abrupt pain relief and/or improvement in signs of bleeding within approximately 8 hours after initial injection; 2=Good: definite pain relief and/or improvement in signs of bleeding within approx. 8 hours after injection, but possibly requiring more than 1 injection after 24-48 hours for complete resolution; 3=Moderate: Probable/slight beneficial effect within 8 hours after initial injection and requires more than 1 injection and 4=None: No improvement or condition worsens within approx. 8 hours after initial injection. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study. |
| Total Number of Exposure Days (EDs) | Up to 3 years | An ED was defined as a 24-hour period in which a participant received one or more doses of rFIXFc injections, with the time of the first injection of rFIXFc defined as the start of the ED. Participant who did not have a particular injection type were counted as having zero injections for that type. |
| Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) Per Participant (Annualized Bleeding Rate [ABR]) | Up to 3 years | ABR was annualized number of bleeding episodes during efficacy period (EP) per participant normalized to a 1-year interval of time. Bleeding episodes were classified as: spontaneous if parent/caregiver/participant records bleeding event when there is no known contributing factor such as definite trauma or antecedent strenuous activity; and traumatic when there is known reason for bleed. ABR=(Number of bleeding episodes during EP/total number of days during EP)\*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc per treatment regimens excluding surgical/rehabilitation periods and large injection intervals (greater than \[\>\]28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study. |
| Number of Injections of rFIXFc Required to Resolve a Bleeding Episode | Up to 3 years | Number of injections of rFIXFc required to resolve a bleeding episode during efficacy period (EP) were reported. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc according to the treatment regimens of the study excluding surgical/rehabilitation periods and large injection intervals (\>28 days). All injections given from the initial sign of a bleed, until the last date/time within the bleed window were counted. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study. |
| Average Dose Per Injection of rFIXFc Required to Resolve a Bleeding Episode | Up to 3 years | The average dose of rFIXFc per injection per bleeding episode was calculated as the average of all doses (IU/kg) administered to treat the bleeding episode during efficacy period (EP). EP begins with the first treatment regimen dose of rFIXFc and ends with the last dose (regardless of the reason for dosing). Surgery/rehabilitation periods are not included in the EP. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study. |
| Change From Baseline in rFIXFc Incremental Recovery (IR) | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, and 144 | Blood samples were taken at trough and Cmax (maximum concentration) for assessment of incremental recovery, measured by the one-stage clotting assay. IR (International Units per deciliter \[IU/dL\] per IU/kg) = (Cmax for FIX activity - Pre-dose FIX activity) (IU/dL)/ Actual dose (IU/kg), where Cmax is 30 minute FIX activity post-dose and FIX activity less than (\<)0.5 IU/dL was set to 0 IU/dL for calculation of IR. |
| Total Annualized rFIXFc Consumption Per Participant for the Prevention and Treatment of Bleeding Episodes | Up to 3 years | Total annualized rFIXFc consumption (in IU/kg) was calculated for each participant as: Annualized consumption = (Total IU/kg of rFIXFc during efficacy period (EP) divided by total number of days during EP)\*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc according to the treatment regimens of the study excluding surgical/rehabilitation periods and large injection intervals (\> 28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study. |
Countries
Australia, Denmark, France, Ireland, Italy, Netherlands, New Zealand, Poland, Sweden, United Kingdom, United States
Participant flow
Recruitment details
The study was conducted at 28 active centers in 11 countries. Participants were screened between 13-Nov-2014 to 23-Jul-2018.
Pre-assignment details
A total of 38 participants were screened. A total of 33 participants were enrolled, 22 participants began study participation on episodic treatment regimen and 11 participants began study participation on prophylactic treatment regimen.
Participants by arm
| Arm | Count |
|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which \>=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR. | 33 |
| Total | 33 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Eligibility Criteria not fulfilled | 2 |
| Overall Study | Physician Decision | 1 |
| Overall Study | Withdrawal by Subject | 2 |
Baseline characteristics
| Characteristic | Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) |
|---|---|
| Age, Continuous | 0.60 years |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants |
| Race/Ethnicity, Customized Black or African-American | 1 Participants |
| Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander | 0 Participants |
| Race/Ethnicity, Customized Other | 4 Participants |
| Race/Ethnicity, Customized Unknown or Not reported | 5 Participants |
| Race/Ethnicity, Customized White | 22 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 33 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 33 |
| other Total, other adverse events | 27 / 33 |
| serious Total, serious adverse events | 23 / 33 |
Outcome results
Primary
Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
Development of an inhibitor was defined as an inhibitor test result of \>= 0.60 Bethesda units per milliliter (BU/mL) that was confirmed by a second test result of \>=0.60 BU/mL from a separate sample, drawn 2 to 4 weeks after the date when the original sample was drawn, with both tests performed by the central laboratory using Nijmegen-modified Bethesda assay.
Time frame: Up to 3 years
Population: Analysis performed on Safety Analysis set which included all participants who had received at least 1 dose of study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay | 3.03 percentage of participants |
Secondary
Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) Per Participant (Annualized Bleeding Rate [ABR])
ABR was annualized number of bleeding episodes during efficacy period (EP) per participant normalized to a 1-year interval of time. Bleeding episodes were classified as: spontaneous if parent/caregiver/participant records bleeding event when there is no known contributing factor such as definite trauma or antecedent strenuous activity; and traumatic when there is known reason for bleed. ABR=(Number of bleeding episodes during EP/total number of days during EP)\*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc per treatment regimens excluding surgical/rehabilitation periods and large injection intervals (greater than \[\>\]28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time frame: Up to 3 years
Population: Analysis performed on Full Analysis Set (FAS) which included all enrolled participants with at least 1 dose of study treatment. Here, number analyzed signifies number of FAS participants who were analyzed in each treatment regimen.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) Per Participant (Annualized Bleeding Rate [ABR]) | Episodic regimen | 0.21 episodes per participant per year |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) Per Participant (Annualized Bleeding Rate [ABR]) | Prophylaxis regimen | 1.24 episodes per participant per year |
Secondary
Annualized Number of Spontaneous Joint Bleeding Episodes
Bleeding episodes were classified as spontaneous if parent/caregiver/participant records a bleeding event when there is no known contributing factor such as a definite trauma or antecedent strenuous activity. Annualized spontaneous joint bleeding episodes=(Total number of spontaneous joint bleeding episodes during efficacy period (EP) divided by total number of days during EP)\*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc per treatment regimen excluding major and minor surgical/rehabilitation periods and large injection intervals (\>28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time frame: Up to 3 years
Population: Analysis performed on FAS. Here, number analyzed signifies number of FAS participants who were analyzed in each treatment regimen.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Annualized Number of Spontaneous Joint Bleeding Episodes | Episodic regimen | 0.00 episodes per participant per year |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Annualized Number of Spontaneous Joint Bleeding Episodes | Prophylaxis regimen | 0.00 episodes per participant per year |
Secondary
Average Dose Per Injection of rFIXFc Required to Resolve a Bleeding Episode
The average dose of rFIXFc per injection per bleeding episode was calculated as the average of all doses (IU/kg) administered to treat the bleeding episode during efficacy period (EP). EP begins with the first treatment regimen dose of rFIXFc and ends with the last dose (regardless of the reason for dosing). Surgery/rehabilitation periods are not included in the EP. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time frame: Up to 3 years
Population: Analysis performed on FAS. Here, number analyzed signifies number of bleeding episodes reported for each treatment regimen.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Average Dose Per Injection of rFIXFc Required to Resolve a Bleeding Episode | Episodic regimen | 88.50 IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Average Dose Per Injection of rFIXFc Required to Resolve a Bleeding Episode | Prophylaxis regimen | 71.92 IU/kg |
Secondary
Change From Baseline in rFIXFc Incremental Recovery (IR)
Blood samples were taken at trough and Cmax (maximum concentration) for assessment of incremental recovery, measured by the one-stage clotting assay. IR (International Units per deciliter \[IU/dL\] per IU/kg) = (Cmax for FIX activity - Pre-dose FIX activity) (IU/dL)/ Actual dose (IU/kg), where Cmax is 30 minute FIX activity post-dose and FIX activity less than (\<)0.5 IU/dL was set to 0 IU/dL for calculation of IR.
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, and 144
Population: Analysis performed on FAS. Here number analyzed signifies number of FAS participants with available data for each visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 12 | 0.0 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 24 | 0.0 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 36 | -0.0 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 48 | -0.0 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 60 | -0.1 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 72 | -0.1 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 84 | -0.1 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 96 | -0.1 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 108 | -0.1 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 120 | -0.1 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 132 | -0.1 IU/dL per IU/kg |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Change From Baseline in rFIXFc Incremental Recovery (IR) | Change at Week 144 | 0.0 IU/dL per IU/kg |
Secondary
Number of Injections of rFIXFc Required to Resolve a Bleeding Episode
Number of injections of rFIXFc required to resolve a bleeding episode during efficacy period (EP) were reported. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc according to the treatment regimens of the study excluding surgical/rehabilitation periods and large injection intervals (\>28 days). All injections given from the initial sign of a bleed, until the last date/time within the bleed window were counted. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time frame: Up to 3 years
Population: Analysis performed on FAS. Here, number analyzed signifies number of bleeding episodes reported for each treatment regimen.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of Injections of rFIXFc Required to Resolve a Bleeding Episode | Episodic regimen | 1.0 injections |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of Injections of rFIXFc Required to Resolve a Bleeding Episode | Prophylaxis regimen | 1.0 injections |
Secondary
Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
Using e-diary, each participant's parent/caregiver rated treatment response to any bleeding episode (BE) at approximately 8 to 12 hours from time of injection and prior to additional doses of rFIXFc given for same BE using 4-point scale:- 1=Excellent: abrupt pain relief and/or improvement in signs of bleeding within approximately 8 hours after initial injection; 2=Good: definite pain relief and/or improvement in signs of bleeding within approx. 8 hours after injection, but possibly requiring more than 1 injection after 24-48 hours for complete resolution; 3=Moderate: Probable/slight beneficial effect within 8 hours after initial injection and requires more than 1 injection and 4=None: No improvement or condition worsens within approx. 8 hours after initial injection. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time frame: Up to 3 years
Population: Analysis performed on FAS. Analysis was based on all injections. Here, number analyzed signifies number of responses to injections reported for each treatment regimen.
| Arm | Measure | Group | Category | Value (COUNT_OF_UNITS) |
|---|---|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Episodic regimen | Excellent or Good | 22 responses to injections |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Episodic regimen | Moderate | 0 responses to injections |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Episodic regimen | None | 0 responses to injections |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Episodic regimen | Response not provided | 58 responses to injections |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Prophylaxis regimen | Excellent or Good | 50 responses to injections |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Prophylaxis regimen | Moderate | 6 responses to injections |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Prophylaxis regimen | None | 1 responses to injections |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale | Prophylaxis regimen | Response not provided | 17 responses to injections |
Secondary
Total Annualized rFIXFc Consumption Per Participant for the Prevention and Treatment of Bleeding Episodes
Total annualized rFIXFc consumption (in IU/kg) was calculated for each participant as: Annualized consumption = (Total IU/kg of rFIXFc during efficacy period (EP) divided by total number of days during EP)\*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc according to the treatment regimens of the study excluding surgical/rehabilitation periods and large injection intervals (\> 28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time frame: Up to 3 years
Population: Analysis performed on FAS. Here, number analyzed signifies number of FAS participants who were analyzed in each treatment regimen.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Total Annualized rFIXFc Consumption Per Participant for the Prevention and Treatment of Bleeding Episodes | Episodic regimen | 203.2 IU per kilogram per participant per year |
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Total Annualized rFIXFc Consumption Per Participant for the Prevention and Treatment of Bleeding Episodes | Prophylaxis regimen | 3175.0 IU per kilogram per participant per year |
Secondary
Total Number of Exposure Days (EDs)
An ED was defined as a 24-hour period in which a participant received one or more doses of rFIXFc injections, with the time of the first injection of rFIXFc defined as the start of the ED. Participant who did not have a particular injection type were counted as having zero injections for that type.
Time frame: Up to 3 years
Population: Analysis performed on safety analysis set.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc) | Total Number of Exposure Days (EDs) | 76.0 days |